Clinical Case Studies — Real Patient Outcomes

Patient profile

Female, 58 years old (initials M.R.). Comorbidities: well-controlled hypothyroidism (Hashimoto, levothyroxine), BMI 27. Right-knee dominant pain for 4 years, conservative management exhausted (NSAIDs, physiotherapy, intra-articular hyaluronic acid). Recreational walker, motivated to avoid arthroplasty.

Presentation & baseline

MRI confirmed bilateral grade II tibiofemoral chondropathy with small focal grade III lesion on medial femoral condyle. Baseline WOMAC total 58/96, pain subscale 14/20, Numeric Rating Scale (NRS) for pain 7/10 at rest, 9/10 with stairs. CRP 4.2 mg/L (mildly elevated). Walked < 1 km before pain forced rest.

Treatment protocol

Combined intravenous + intra-articular mesenchymal stem cell (MSC) protocol from a COFEPRIS-certified umbilical-cord-derived cell bank. Single IV infusion of 100 million MSCs, plus two right-knee intra-articular injections of 30 million MSCs each, spaced 4 weeks apart. Adjunct: oral collagen peptides and a 12-week guided exercise plan led by our physical-rehab team.

Outcomes at follow-up

At 6 months: WOMAC total 32/96 (−45%), pain subscale 6/20, NRS rest 2/10, stairs 4/10. CRP 1.8 mg/L. Walking distance > 3 km without pain interruption. At 12 months: improvements largely sustained (WOMAC 34/96, NRS rest 3/10) with mild seasonal flare in month 9 that resolved with rehab. At 24 months: WOMAC 38/96, patient continues recreational walking 4x/week. No need for arthroplasty referral.

Honest assessment

Responder. Profile fit the published candidacy literature (grade II-III, BMI < 30, motivated, intact muscle tone). Sustained benefit at 24 months. Honest caveat: the patient's strong adherence to the rehab plan likely contributed as much as the cellular component; outcome cannot be attributed to MSCs in isolation.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Female, 42 years old (initials L.P.). SLE diagnosed 9 years prior, currently on hydroxychloroquine + low-dose prednisone (7.5 mg/day) + mycophenolate. Persistent arthralgia, fatigue and butterfly rash despite optimized DMARD regimen. Followed by her primary rheumatologist throughout; we coordinated treatment as adjunct.

Presentation & baseline

Baseline SLEDAI-2K 12 (moderate activity). Anti-dsDNA 240 IU/mL (elevated). Complement C3/C4 reduced. Fatigue Severity Scale 6.4/7. Daily prednisone goal: taper to < 5 mg/day, repeatedly unsuccessful in the prior 18 months due to symptom rebound.

Treatment protocol

IV mesenchymal stem cell infusion, 150 million MSCs from umbilical-cord source. Two infusions spaced 8 weeks apart. Adjunct: IV nutrition (B-complex, vitamin C, glutathione) on infusion day. All decisions on DMARD taper kept under the rheumatologist's direction — we explicitly do not adjust immunosuppressants.

Outcomes at follow-up

At 6 months: SLEDAI-2K 8 (−33%). Anti-dsDNA 165 IU/mL. FSS 4.8/7. Rheumatologist successfully tapered prednisone to 5 mg/day. At 12 months: SLEDAI-2K 7.8 (−35% from baseline), C3/C4 improved but not normalized, prednisone sustained at 5 mg/day with no flare. Rash unchanged. At 24 months: stable activity, no organ involvement, prednisone at 5 mg/day; patient reports meaningful quality-of-life gain.

Honest assessment

Partial responder. Achieved the practical goal (steroid taper) but did not enter serological remission. We consider this a meaningful clinical win because the steroid taper alone reduces long-term osteoporosis and cataract risk substantially. SLE is a chronic disease — MSC therapy is supportive, never curative, and her rheumatologist remains the primary decision-maker.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Male, 38 years old (initials J.A.). Progressive frontotemporal hair loss over 6 years, family history (father Norwood V at 50). Previously tried oral finasteride for 8 months — discontinued due to libido side effects. Currently on topical minoxidil 5% twice daily for 14 months with modest stabilization but no regrowth.

Presentation & baseline

Norwood-Hamilton stage III with diffuse miniaturization in the mid-scalp. Trichoscopy showed hair-shaft diameter variability > 20%. Photographic baseline established at standardized lighting and angle. Patient declined hair transplantation. Realistic expectations discussed: stabilization more likely than full regrowth.

Treatment protocol

Three-session scalp protocol spaced 4 weeks apart: each session combined platelet-rich plasma (PRP) prepared from autologous double-spin centrifugation with topical exosome serum applied immediately after microneedling. Maintenance: continued topical minoxidil throughout, no new oral therapy added.

Outcomes at follow-up

At 3 months: subjective decrease in daily shed, no visible regrowth yet. At 6 months: trichoscopy hair density +18%, photographic comparison showed visible thickening in mid-scalp. At 9 months: hair density +25% vs baseline, hair-shaft diameter variability reduced to 12%. Patient elected for a single maintenance PRP session at 12 months. At 18 months: gains largely sustained, patient continues minoxidil.

Honest assessment

Responder. Candidacy was favorable (early Norwood stage, no extensive bald patches, motivated, complementary topical therapy continued). PRP + exosomes have the strongest scalp-application evidence in our menu; we steer patients with advanced Norwood VI–VII toward surgical evaluation instead.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Male, 51 years old (initials R.G.). Mechanical low back pain with intermittent L5 radiculopathy for 18 months. Active recreational runner forced to stop. Conservative management exhausted (physical therapy, NSAIDs, two epidural steroid injections — only short-term benefit). Surgical consultation recommended microdiscectomy; patient sought a non-surgical option first.

Presentation & baseline

MRI showed L4-L5 paracentral disc protrusion with Pfirrmann III degeneration, no severe neural compression. Baseline Oswestry Disability Index (ODI) 48% (severe disability), NRS pain 7/10. Straight-leg raise positive at 50° on the right. Could not run, sit longer than 30 minutes, or sleep through the night.

Treatment protocol

Image-guided intradiscal MSC injection (40 million MSCs delivered into the L4-L5 disc nucleus under fluoroscopic guidance and sterile technique). Concurrent intra-foraminal PRP at the L5 root sleeve. Single procedure. Adjunct: 16-week structured spine-rehabilitation program with our physical-rehab team focused on lumbopelvic stabilization.

Outcomes at follow-up

At 3 months: ODI 30%, NRS pain 4/10, intermittent radiculopathy resolved. At 6 months: ODI 18%, NRS pain 2/10, sleeping through the night, sitting tolerance > 2 hours. At 12 months: ODI 14% (−40% from baseline), patient returned to recreational running, progressively increasing distance to 8 km. MRI repeat showed unchanged disc morphology — clinical improvement out of proportion to imaging change.

Honest assessment

Responder. Clinical recovery exceeded what the imaging would predict — likely reflects MSC anti-inflammatory effect at the disc–root interface plus the rehab program's effect on movement quality. Honest caveat: intradiscal MSC therapy remains experimental for disc disease; we limit it to motivated patients with Pfirrmann II–III who explicitly want to avoid surgery and accept the uncertainty.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Female, 64 years old (initials C.D.). Healthy active retiree, no chronic disease, BMI 24. Presenting concerns: progressive fatigue, declining sleep quality, mild cognitive cloudiness, declining exercise tolerance. Sought a longevity/wellness program after retirement. Realistic expectations discussed up front: we cannot reverse biological age, but we can target specific physiological levers.

Presentation & baseline

Baseline labs: HbA1c 5.6%, hsCRP 2.4 mg/L (mildly elevated), homocysteine 12 µmol/L, NAD+ low-normal, vitamin D 22 ng/mL (insufficient), DHEA-S below age-adjusted reference. Self-reported Pittsburgh Sleep Quality Index 11 (poor). Energy 4/10. Mood and motivation otherwise intact.

Treatment protocol

Twelve-month structured program: single IV MSC infusion (100 million MSCs) at month 1; NAD+ IV infusion series (10 sessions over 6 months); supervised peptide protocol (BPC-157 cycle plus selective GHK-Cu for skin); vitamin D + omega-3 + B-complex supplementation; sleep hygiene coaching; quarterly biomarker follow-up. The single most expensive element (MSC infusion) was discussed as 'helpful adjunct' rather than central — we framed the program around the cheaper but cumulatively meaningful interventions.

Outcomes at follow-up

At 6 months: self-reported energy 7/10, PSQI 6 (improved), vitamin D 38 ng/mL, hsCRP 1.1 mg/L, homocysteine 9 µmol/L. At 12 months: energy stable at 7/10, PSQI 5, hsCRP 0.9 mg/L, NAD+ mid-range, HbA1c 5.4%, DHEA-S within age-adjusted reference. Subjectively: cognitive cloudiness improved, returned to recreational tennis 2x/week, sleep 'completely transformed' per patient report.

Honest assessment

Responder by both subjective and biomarker metrics. Honest caveat: most of the biomarker shift is plausibly attributable to the cheaper interventions (vitamin D repletion, NAD+ series, sleep hygiene, omega-3) rather than the single MSC infusion. We share this case as a transparent example of what a multi-modal anti-aging program can and cannot do — energy and sleep, yes; reversing chronological age, no.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Male, 55 years old (initials E.S.). Six-year history of progressive ED. Comorbidities: well-controlled type 2 diabetes (HbA1c 6.4%), hypertension on losartan, BMI 28. PDE5 inhibitors partial benefit only at maximum dose. Penile Doppler ultrasound suggested vasculogenic component. Spouse present in initial consultation; both motivated to avoid intracavernosal injection therapy or implant.

Presentation & baseline

Baseline IIEF-5 score 12 (moderate ED). Erection Hardness Score (EHS) 2 (mostly soft, sufficient for penetration only with sustained sildenafil). Morning erections rare. Penile Doppler peak systolic velocity 28 cm/s on the right cavernosal artery (borderline). Cardiovascular risk reviewed and cleared by treating cardiologist.

Treatment protocol

Three-session intracavernosal protocol spaced 4 weeks apart: PRP (autologous, double-spin) combined with 20 million MSCs per session, administered with topical anesthesia. Adjunct: low-intensity extracorporeal shockwave therapy (LiSWT) 6 sessions over the same period. Patient continued PDE5 inhibitor on demand.

Outcomes at follow-up

At 3 months: IIEF-5 17, EHS 3, morning erections returning intermittently. At 6 months: IIEF-5 21 (mild ED bracket), EHS 3, spontaneous erections recovered, satisfaction reported by patient and spouse. PDE5 use reduced to occasional rather than required. At 12 months: IIEF-5 sustained at 20, EHS 3, patient continues lifestyle program. At 18 months: gradual decline to IIEF-5 18 — patient elected single maintenance PRP-only session.

Honest assessment

Responder. Candidacy fit the literature: vasculogenic component, controlled diabetes, partial response to oral therapy, cardiovascular clearance. Honest caveat: ED is multi-factorial and benefit was almost certainly augmented by his improved metabolic control and the LiSWT sessions; cellular component cannot be isolated as the only driver. We do not promise penile-implant-equivalent results — this is restoration of function, not maximization.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Female, 35 years old (initials A.T.). Relapsing-remitting MS diagnosed 5 years prior. Three documented relapses in the preceding 36 months. Current disease-modifying therapy: ocrelizumab infusions every 6 months, well-tolerated. Sought adjunctive options for fatigue and cognitive symptoms not addressed by DMT. Treating neurologist consulted and supportive of adjunctive evaluation.

Presentation & baseline

Baseline EDSS 2.0 (minimal disability). MRI: 8 stable T2 lesions, no enhancing lesions on baseline scan. Fatigue Severity Scale 5.8/7. Cognitive symptoms self-rated: subjective decline in word retrieval and reading focus over 18 months. Disease activity stable on DMT but quality-of-life burden persistent.

Treatment protocol

IV mesenchymal stem cell infusion, 150 million MSCs from umbilical-cord source. Two infusions spaced 12 weeks apart. Adjunct: IV glutathione + B-complex on infusion day; cognitive rehabilitation program coordinated externally. Critical decision rule: any imaging change or relapse triggers immediate neurologist re-evaluation and pauses additional sessions — we explicitly do not treat through worsening disease activity.

Outcomes at follow-up

At 6 months: FSS 4.2/7, subjective cognitive improvement, EDSS unchanged at 2.0. At 12 months: surveillance MRI showed no new lesions and no enhancement; FSS 4.0/7; cognitive screening (SDMT) +6 points vs baseline. At 24 months: EDSS stable at 2.0, no clinical relapses since the protocol, MRI stable, ocrelizumab continued per neurologist. Patient continues working full-time.

Honest assessment

Stable / partial responder. We cannot claim MSCs prevented relapses — RRMS course is variable and ocrelizumab itself is highly effective. What we can say honestly: the patient's symptomatic burden (fatigue, cognition) improved, no new imaging activity emerged during follow-up, and the protocol was integrated cleanly with her primary DMT. MSC therapy for MS remains under active investigation; we treat only with active neurologist coordination and never as a replacement for DMT.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.

Patient profile

Female, 72 years old (initials P.M.). End-stage left-knee osteoarthritis for 7 years, BMI 32. Comorbidities: type 2 diabetes (HbA1c 7.2%), mild aortic stenosis, osteoporosis. Conservative management exhausted. Family had pressured against arthroplasty due to anesthesia concerns; patient sought 'anything that might delay surgery.' We explicitly counseled that MSC therapy is not validated for grade IV OA and that arthroplasty remained the standard of care.

Presentation & baseline

MRI: grade IV chondral loss with bone-on-bone contact, large subchondral cysts, marginal osteophytes. Baseline WOMAC total 78/96, NRS pain 9/10. Could ambulate < 100 meters with cane. Surgical risk was elevated but not prohibitive per cardiology. Realistic expectation discussed openly: at best, modest pain reduction; arthroplasty would still be the definitive solution.

Treatment protocol

Combined IV MSC (100 million) + two intra-articular MSC sessions (30 million each, 6 weeks apart) into the left knee. Adjunct: weight-loss counseling and gentle aquatic rehabilitation. No procedural complications.

Outcomes at follow-up

At 3 months: WOMAC 70/96, NRS 7/10 — modest pain reduction, no functional change. At 6 months: WOMAC 72/96, NRS 7/10 — gains had eroded. At 9 months: patient elected total knee arthroplasty after coordinated discussion with us and her orthopedic surgeon. Post-operative recovery uneventful. At 18 months post-arthroplasty (27 months from our index treatment): WOMAC 22/96, NRS 2/10, walking unassisted.

Honest assessment

Non-responder. We publish this case deliberately. Grade IV bone-on-bone OA is outside the indication envelope where MSC therapy has reasonable evidence — we discussed that openly before treating and the patient understood the limits. The honest takeaway: the right intervention here was always arthroplasty, and our role ended up being to support her decision-making rather than substitute for the surgery she ultimately needed. Sharing non-responders is the only way to make the rest of this page believable.

Anonymized for privacy. Individual results vary. This case study describes the clinical course of one patient and is not a guarantee of any specific outcome.